Clinical Trials Logo

Relapsing Multiple Sclerosis clinical trials

View clinical trials related to Relapsing Multiple Sclerosis.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT04928313 Completed - Clinical trials for Relapsing Multiple Sclerosis

Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran

Start date: April 12, 2015
Phase:
Study type: Observational

This trial was an obsevational phase IV prospective multicenter study designed to evaluate the safety and effectiveness of Cinnomer® in patients with MS in Iran. The primary objective of this study was safety assessment of Cinnomer® Secondary objectives were: - Effectiveness assessment of Cinnomer® - Assessment of the patients' QoL - Evaluation of the patients' depression status

NCT ID: NCT04847596 Completed - Clinical trials for Relapsing Multiple Sclerosis

A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Start date: May 21, 2021
Phase:
Study type: Observational

This is a single arm, pilot multicenter prospective study in up to 22 participants with relapsing multiple sclerosis. Patients screened for the study can either be scheduled for vaccine, have received a single vaccine with a scheduled second dose, or already completed full course (two dose) vaccination. Fully vaccinated participants must be able to complete immune assay No.1 ≥ 14 days after the second dose of vaccine

NCT ID: NCT04667117 Completed - Clinical trials for Relapsing Multiple Sclerosis

A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Start date: January 14, 2021
Phase: Phase 4
Study type: Interventional

To assess whether participants treated with ofatumumab 20 mg subcutaneous (s.c.) administered once every 4 weeks (q4) can mount an adequate immune response to inactivated influenza vaccine as measured by humoral responses compared to participants on an iDMT.

NCT ID: NCT04626921 Completed - Clinical trials for Relapsing Multiple Sclerosis

A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis

VISIONMS-LTE
Start date: October 22, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

Open-label, long-term extension study available to participants who have completed CNMAu8.201.

NCT ID: NCT03889639 Completed - Clinical trials for Relapsing Multiple Sclerosis

Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis

Start date: March 29, 2019
Phase: Phase 2
Study type: Interventional

Primary Objective: To determine the dose-response relationship for SAR442168 to reduce the number of new active brain lesions. Secondary Objectives: - To evaluate efficacy of SAR442168 on disease activity as assessed by imaging measures. - To evaluate the safety and tolerability of SAR442168.

NCT ID: NCT03856619 Completed - Clinical trials for Relapsing Multiple Sclerosis

To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis

SAFE
Start date: March 27, 2019
Phase: Phase 4
Study type: Interventional

Primary Objective: To describe the safety of teriflunomide in patients with relapsing forms of multiple sclerosis. Secondary Objective: To describe the efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis.

NCT ID: NCT03623243 Completed - Multiple Sclerosis Clinical Trials

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

EXCHANGE
Start date: February 14, 2019
Phase: Phase 3
Study type: Interventional

To assess safety and tolerability of patients converting from approved Relapsing Multiple Sclerosis (RMS) Disease Modifying Therapies (DMTs) to siponimod.

NCT ID: NCT03257358 Completed - Clinical trials for Relapsing Multiple Sclerosis

A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod

FLUENT
Start date: September 19, 2017
Phase: Phase 4
Study type: Interventional

A study of immune phenotype biomarkers in patients with Relapsing Multiple Sclerosis (RMS) after treatment with 0.5mg fingolimod

NCT ID: NCT03249714 Completed - Clinical trials for Relapsing Multiple Sclerosis

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

Start date: March 15, 2018
Phase: Phase 2
Study type: Interventional

The study provided efficacy, safety, and pharmacokinetics (PK) data for patients with relapsing multiple sclerosis (RMS) in Japan and the other countries

NCT ID: NCT02792218 Completed - Clinical trials for Relapsing Multiple Sclerosis

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

ASCLEPIOS I
Start date: September 20, 2016
Phase: Phase 3
Study type: Interventional

To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis